Watch Melted by Hiroshima Bomb Auctioned for $31,000

This photo provided by RR Auction shows a watch melted during the Aug.6, 1945 bombing of Hiroshima. The watch is frozen in time at the moment of detonation of the atomic bomb over the city during the closing days of World War ll, sold at auction Thursday, Feb. 22, 2024 for more than $31,000. Nikki Brickett - handout one time use, ASSOCIATED PRESS
This photo provided by RR Auction shows a watch melted during the Aug.6, 1945 bombing of Hiroshima. The watch is frozen in time at the moment of detonation of the atomic bomb over the city during the closing days of World War ll, sold at auction Thursday, Feb. 22, 2024 for more than $31,000. Nikki Brickett - handout one time use, ASSOCIATED PRESS
TT

Watch Melted by Hiroshima Bomb Auctioned for $31,000

This photo provided by RR Auction shows a watch melted during the Aug.6, 1945 bombing of Hiroshima. The watch is frozen in time at the moment of detonation of the atomic bomb over the city during the closing days of World War ll, sold at auction Thursday, Feb. 22, 2024 for more than $31,000. Nikki Brickett - handout one time use, ASSOCIATED PRESS
This photo provided by RR Auction shows a watch melted during the Aug.6, 1945 bombing of Hiroshima. The watch is frozen in time at the moment of detonation of the atomic bomb over the city during the closing days of World War ll, sold at auction Thursday, Feb. 22, 2024 for more than $31,000. Nikki Brickett - handout one time use, ASSOCIATED PRESS

A watch melted during the August 6, 1945, bombing of Hiroshima, Japan, has sold for more than $31,000 at auction. The watch is frozen in time at the moment of the detonation of an atomic bomb over the Japanese city — 8:15 a.m. — during the closing days of World War II, according to Boston-based RR Auction. The winning bid in the auction that ended Thursday was $31,113, reported the Associated Press (AP). The artifact was recovered from the ruins of Hiroshima and offers a glimpse into the immense destruction of the first atomic bomb detonated over a city.

The small brass-tone watch, a rare survivor from the blast zone, was auctioned alongside other historically significant items. Despite the cloudiness of the crystal caused by the blast, the watch’s hands remain halted at 8:15 a.m. — the moment when the B-29 Enola Gay dropped the “Little Boy” atomic bomb. The auction house said that according to the item’s consignor, a British soldier retrieved the wristwatch from the ruins of the city while on a mission to provide emergency supplies and assess post-conflict reconstruction needs. “It is our fervent hope that this museum-quality piece will stand as a poignant educational symbol, serving to not only remind us of the tolls of war but also to underscore the profound, destructive capabilities that humanity must strive to avoid. This wristwatch, for instance, marks the exact moment in time when history changed forever,” said Bobby Livingston, executive vice president at RR Auction. The winning bidder opted to remain anonymous. Other items featured in the auction included a signed copy of former Chinese leader Mao Zedong’s ‘The Little Red Book’, which sold for $250,000; a signed check from George Washington — one of two known checks signed as president to ever come to market — which sold for $135,473; and Buzz Aldrin’s Apollo 11 Lunar Module Prep Checklist, which sold for $76,533.



Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
TT

Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)

The anti-obesity drug Ozempic could slow down ageing and has “far-reaching benefits” beyond what was imagined, researchers have suggested.

Multiple studies have found semaglutide (available under the brand names Wegovy and Ozempic) reduced the risk of death in people who were obese or overweight and had cardiovascular disease without diabetes, The Independent reported.

Responding to research published in JACC, the flagship journal of the American College of Cardiology, Professor Harlan M Krumholz from the Yale School of Medicine, said: “Semaglutide, perhaps by improving cardiometabolic health, has far-reaching benefits beyond what we initially imagined.”

He added: “These ground-breaking medications are poised to revolutionise cardiovascular care and could dramatically enhance cardiovascular health.”

Multiple reports also quoted Professor Krumholz saying: “Is it a fountain of youth?”

He said: “I would say if you’re improving someone’s cardiometabolic health substantially, then you are putting them in a position to live longer and better.

“It’s not just avoiding heart attacks. These are health promoters. It wouldn’t surprise me that improving people’s health this way actually slows down the ageing process.”

The studies, presented at the European Society of Cardiology Conference 2024 in London, were produced from the Select trial which studied 17,604 people aged 45 or older who were overweight or obese and had established cardiovascular disease but not diabetes.

They received 2.4 mg of semaglutide or a placebo and were tracked for more than three years.

A total of 833 participants died during the study with 5 percent of the deaths were related to cardiovascular causes and 42 per cent from others.

Infection was the most common cause death beyond cardiovascular, but it occurred at a lower rate in the semaglutide group than the placebo group.

People using the weight-loss drug were just as likely to catch Covid-19, but they were less likely to die from it – 2.6 percent dying among those on semaglutide versus 3.1 per cent on the placebo.

Researchers found women experienced fewer major adverse cardiovascular events, but semaglutide “consistently reduced the risk” of adverse cardiovascular outcomes regardless of sex.

Dr Benjamin Scirica, lead author of one of the studies and a professor of cardiovascular medicine at Harvard Medical School, said: “The robust reduction in non-cardiovascular death, and particularly infections deaths, was surprising and perhaps only detectable because of the Covid-19-related surge in non-cardiovascular deaths.

“These findings reinforce that overweight and obesity increases the risk of death due to many etiologies, which can be modified with potent incretin-based therapies like semaglutide.”

Dr Jeremy Samuel Faust, an emergency medicine physician at Brigham and Women’s Hospital, praised the researchers for adapting the study to look at Covid-19 when the pandemic started.

He said the findings that the weight-loss drug to reduce Covid-19 mortality rates were “akin to a vaccine against the indirect effects of a pathogen.”